Pfizer (PFE) said Saturday that its Phase 3 BREAKWATER study showed a 61% objective response rate for the BRAFTOVI combination therapy in patients with BRAF V600E-mutant metastatic colorectal cancer, compared to 40% for standard chemotherapy, based on an independent review.
The BRAFTOVI treatment, which includes cetuximab and mFOLFOX6, has been approved by the FDA for newly diagnosed patients with this mutation, the company stated.
Patients treated with the BRAFTOVI combination had a median response duration of 13.9 months, compared to 11.1 months for those receiving normal chemotherapy, while early overall survival data showed favorable results for the new treatment, Pfizer added.
Pfizer said the safety profile of the BRAFTOVI combination was in line with the known effects of the individual treatments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。